We are SmallCaps.Us

  • Smallcaps is an online platform that introduces and follows-up high potential U.S. and Canadian small cap stocks.
  • We publish unique content about those companies every Saturday.
  • Why you should sign up for our newsletter? Because an average gain of 210% since 2003 proves that our small cap picks are also perfect for your portfolio.

Latest Articles

Hemispherx’ Institutional Buying

While we’re still waiting for the FDA to make a decision regarding Hemisperx Biopharma’s (HEB – $2.00) NDA for Ampligen to treat Chronic Fatigue Syndrome (CFS), mutual funds have been big buyers of HEB’s shares. In the second quarter, ending June 30, 2009, mutual funds have added 8.36 million shares of Hemispherx, or 6.6% of total shares outstanding, to their […]

Read more

Clearfield Inc. (CLFD) In The News

At a time of year when the number of press releases is relatively low, one Company, that we have been following for some time, stood out this week with two announcements: Clearfield Inc. (CLFD – $1.77) . Clearfield, which manufactures and sells fiber distribution systems, optical components, outside plant cabinets, and fiber and copper cable assemblies for the telecommunications industry, […]

Read more

Another Ace Up Our Sleeve

Next to Hemispherx Biopharma Inc. (+ 572% since our recommendation) and Orsus Xelent Inc (+ 65% since our recommendation), we have a few more aces up our sleeve. Take, for instance, Global Green Solutions Inc. (GGRN – $0.12) , which we first recommended at $0.06 a few months ago, is making progress in both its business units: Greensteam, a commercial […]

Read more

Baldwin Technology Company – Initial Interview

Our guest today is Mr. Karl Puehringer, President and CEO of Baldwin Technology Co. Inc. (BLD – $0.91). Baldwin Technology Company, Inc., together with its subsidiaries, engages primarily in the development, manufacture, and sale of process automation equipment for the printing and publishing industry. Mr. Puehringer discusses the Company and the markets it operates in. Click the start button underneath […]

Read more

Hemispherx Biopharma: Wilder and Wilder

A few weeks ago, we wrote Hemispherx Biopharma’s (HEB – $2.73) shares were on a rollercoaster and it seems the ride is getting wilder and wilder. Obviously, there’s a tremendous amount of speculation about the FDA’s decision to approve Ampligen for Chronic Fatigue Syndrome (CFS). Based on all the public information out there, you have to form an opinion, and […]

Read more

The Hemispherx (HEB) Controversy

For many this is starting to look like a soap opera, but contrary to the TV version, this is extremely exciting. Obviously, we’re talking about Hemispherx Biopharma (HEB) and the big question will the FDA give its thumbs up to bring Ampligen to the market. The introduction to the next episode was given on Tuesday morning when HEB issued a […]

Read more
1 114 115 116 117 118 119